PMC:7074432 / 13583-14464 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"473","span":{"begin":60,"end":64},"obj":"Gene"},{"id":"474","span":{"begin":216,"end":247},"obj":"Gene"},{"id":"475","span":{"begin":249,"end":253},"obj":"Gene"},{"id":"476","span":{"begin":297,"end":301},"obj":"Gene"},{"id":"477","span":{"begin":479,"end":483},"obj":"Gene"},{"id":"478","span":{"begin":634,"end":638},"obj":"Gene"},{"id":"479","span":{"begin":705,"end":731},"obj":"Gene"},{"id":"480","span":{"begin":20,"end":28},"obj":"Species"},{"id":"481","span":{"begin":867,"end":876},"obj":"Species"},{"id":"482","span":{"begin":4,"end":11},"obj":"Species"},{"id":"483","span":{"begin":575,"end":586},"obj":"Chemical"},{"id":"484","span":{"begin":640,"end":651},"obj":"Chemical"},{"id":"485","span":{"begin":765,"end":776},"obj":"Chemical"}],"attributes":[{"id":"A473","pred":"tao:has_database_id","subj":"473","obj":"Gene:59272"},{"id":"A474","pred":"tao:has_database_id","subj":"474","obj":"Gene:22848"},{"id":"A475","pred":"tao:has_database_id","subj":"475","obj":"Gene:22848"},{"id":"A476","pred":"tao:has_database_id","subj":"476","obj":"Gene:22848"},{"id":"A477","pred":"tao:has_database_id","subj":"477","obj":"Gene:22848"},{"id":"A478","pred":"tao:has_database_id","subj":"478","obj":"Gene:22848"},{"id":"A479","pred":"tao:has_database_id","subj":"479","obj":"Gene:2580"},{"id":"A480","pred":"tao:has_database_id","subj":"480","obj":"Tax:2697049"},{"id":"A481","pred":"tao:has_database_id","subj":"481","obj":"Tax:2697049"},{"id":"A482","pred":"tao:has_database_id","subj":"482","obj":"Tax:694009"},{"id":"A483","pred":"tao:has_database_id","subj":"483","obj":"MESH:C000596027"},{"id":"A484","pred":"tao:has_database_id","subj":"484","obj":"MESH:C000596027"},{"id":"A485","pred":"tao:has_database_id","subj":"485","obj":"MESH:C000596027"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T374","span":{"begin":20,"end":28},"obj":"SP_7"},{"id":"T373","span":{"begin":60,"end":64},"obj":"G_3;PG_10;PR:000003622"},{"id":"T372","span":{"begin":129,"end":134},"obj":"UBERON:0000170"},{"id":"T371","span":{"begin":191,"end":202},"obj":"GO:0006897"},{"id":"T370","span":{"begin":216,"end":247},"obj":"PR:000003526"},{"id":"T369","span":{"begin":249,"end":253},"obj":"PR:000003526"},{"id":"T368","span":{"begin":297,"end":301},"obj":"PR:000003526"},{"id":"T367","span":{"begin":479,"end":483},"obj":"PR:000003526"},{"id":"T366","span":{"begin":565,"end":574},"obj":"CHEBI:66921;CHEBI:66921"},{"id":"T365","span":{"begin":575,"end":586},"obj":"DG_41"},{"id":"T364","span":{"begin":634,"end":638},"obj":"PR:000003526"},{"id":"T363","span":{"begin":640,"end":651},"obj":"DG_41"},{"id":"T362","span":{"begin":674,"end":685},"obj":"GO:0006897"},{"id":"T361","span":{"begin":705,"end":731},"obj":"PR:000007805"},{"id":"T360","span":{"begin":765,"end":776},"obj":"DG_41"},{"id":"T359","span":{"begin":867,"end":876},"obj":"SP_7"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T27","span":{"begin":46,"end":51},"obj":"Body_part"},{"id":"T28","span":{"begin":112,"end":117},"obj":"Body_part"},{"id":"T29","span":{"begin":129,"end":134},"obj":"Body_part"},{"id":"T30","span":{"begin":231,"end":238},"obj":"Body_part"},{"id":"T31","span":{"begin":696,"end":703},"obj":"Body_part"}],"attributes":[{"id":"A27","pred":"fma_id","subj":"T27","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A28","pred":"fma_id","subj":"T28","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A29","pred":"fma_id","subj":"T29","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A30","pred":"fma_id","subj":"T30","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A31","pred":"fma_id","subj":"T31","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T67","span":{"begin":46,"end":51},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T68","span":{"begin":112,"end":117},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T69","span":{"begin":129,"end":134},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T70","span":{"begin":136,"end":138},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T71","span":{"begin":151,"end":160},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T72","span":{"begin":261,"end":262},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T150","span":{"begin":231,"end":238},"obj":"Chemical"},{"id":"T151","span":{"begin":372,"end":379},"obj":"Chemical"},{"id":"T152","span":{"begin":456,"end":463},"obj":"Chemical"},{"id":"T153","span":{"begin":552,"end":574},"obj":"Chemical"},{"id":"T154","span":{"begin":565,"end":574},"obj":"Chemical"},{"id":"T155","span":{"begin":696,"end":703},"obj":"Chemical"}],"attributes":[{"id":"A150","pred":"chebi_id","subj":"T150","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A151","pred":"chebi_id","subj":"T151","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A152","pred":"chebi_id","subj":"T152","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A153","pred":"chebi_id","subj":"T153","obj":"http://purl.obolibrary.org/obo/CHEBI_76617"},{"id":"A154","pred":"chebi_id","subj":"T154","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A155","pred":"chebi_id","subj":"T155","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T16","span":{"begin":151,"end":160},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T17","span":{"begin":169,"end":202},"obj":"http://purl.obolibrary.org/obo/GO_0006898"},{"id":"T18","span":{"begin":191,"end":202},"obj":"http://purl.obolibrary.org/obo/GO_0006897"},{"id":"T19","span":{"begin":558,"end":574},"obj":"http://purl.obolibrary.org/obo/GO_0033673"},{"id":"T20","span":{"begin":674,"end":685},"obj":"http://purl.obolibrary.org/obo/GO_0006897"},{"id":"T21","span":{"begin":705,"end":711},"obj":"http://purl.obolibrary.org/obo/GO_0016538"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T91","span":{"begin":0,"end":290},"obj":"Sentence"},{"id":"T92","span":{"begin":291,"end":333},"obj":"Sentence"},{"id":"T93","span":{"begin":334,"end":443},"obj":"Sentence"},{"id":"T94","span":{"begin":444,"end":503},"obj":"Sentence"},{"id":"T95","span":{"begin":504,"end":618},"obj":"Sentence"},{"id":"T96","span":{"begin":619,"end":733},"obj":"Sentence"},{"id":"T97","span":{"begin":734,"end":881},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}

{"project":"2_test","denotations":[{"id":"32201439-32032529-47219439","span":{"begin":878,"end":880},"obj":"32032529"},{"id":"T4041","span":{"begin":878,"end":880},"obj":"32032529"}],"text":"The SARSCoV and the 2019nCoV both enters host cells through ACE2 receptormediated entry, especially through AT2 cells present in lungs.[36] Downstream signaling of this receptor mediates the endocytosis process, and AP2-associated protein kinase 1 (AAK1) plays a major role in this process. Thus, AAK1 represents an important target. Richardson et al., 2020 evaluated 378 ligands, of which 47 were already approved for use in other conditions. Among these ligands, six inhibited AAK1 with high affinity. Considering the side effect profile, they found janus kinase inhibitor baricitinib to be the most important agent. In addition to AAK1, baricitinib also binds to another endocytosis regulator protein (cyclin G-associated kinase). Thus, the authors suggest that baricitinib can be evaluated in the in vitro conditions as well as in the clinical trial settings for 2019-nCoV.[37]"}